Biotechs taking an advantage of new Hong Kong exchange rules have been told to expect lower valuations, after Chinese pioneer Ascletis Pharma’s shares plunged nearly 45% in the first month
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.